[China Pharmaceutical Network Enterprise News] Ningbo Menova Pharmaceutical Co., Ltd. is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates. Recently, Manova was successfully listed on the main board of the Shanghai Stock Exchange, becoming the first listed company in Ningbo that specializes in manufacturing specialty medical raw materials and pharmaceutical intermediates.

Minovar is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates. The main categories include cardiovascular, gastrointestinal and central nervous drugs. The company's main products are raw materials and intermediates such as valsartan, losartan, candesartan, perindopril, rosuvastatin, atorvastatin, clopidogrel and esomeprazole. The diversified structure of products strengthens the company's ability to resist risks and provides the company with a stable source of income and profit. The public offering of 30 million A-shares will bring the total share capital to 120 million after the issuance, all of which are tradable shares. After deducting the issuance expenses, the funds raised from the issuance will be used for the construction project of an annual output of 3 billion tablets (tablets) for export solid preparations and the construction of a drug research and development center.

Focus on "intelligent manufacturing" characteristic APIs and pharmaceutical intermediates for more than ten years

Manova closely follows the forefront of the market, has obtained 32 invention patents and a number of international or domestic leading research results, formed a rich product range and a competitive product structure, as a technologically advanced international characteristic API research and development, Production and sales group companies, the company's product lines are concentrated in the cardiovascular and gastrointestinal fields, and become one of the companies that export the largest variety of European specialty APIs in Europe. It has a certain corporate reputation and reputation in Europe.

The company has established R&D centers (institutes) in Ningbo, Shangyu, and Hangzhou, and technical centers in Shangyu and Guangde. The company and its subsidiaries have 71 patents (including 32 invention patents). At present, the company's research and development expenses account for more than 4% of its operating income, and it has won 15 scientific and technological achievements and technical honors. The company’s R&D department has advanced analytical instruments and R&D facilities, as well as a group of 14 foreign R&D personnel with international vision and experience, mainly from India, including 5 doctors and 6 masters. Most of the R&D personnel have more than ten years. Work experience in multinational pharmaceutical companies.

The company attaches great importance to customer development and maintenance. Over the years, with its high-quality product quality and strict quality control system, it has owned a number of stable and high-quality customers, including KRKA, GEDEON RICHTER PLC. The products can be sold directly to the European market for the stable foreign major customers.

The company will use its R&D advantage platform, complete synthetic production equipment and advanced synthesis technology to enhance the company's core competitiveness and market position of raw materials and pharmaceutical intermediates; at the same time, it is committed to the development of new drugs with independent intellectual property rights and accelerates its development in the field of preparations. , To become a well-known pharmaceutical company in China and even the world, and create an excellent "Minovar" pharmaceutical brand.

Close to the listing opportunity, increase research and development efforts to expand market space

Manova took the opportunity of this stock issuance and listing, focusing on the development of the chemical raw material medicine industry, further integrating and optimizing the company’s existing resources, based on the pursuit of high-end profits in the industry chain, and developing products with higher added value. Carry out the production of pharmaceutical preparations and represent the processing and production of large-scale pharmaceutical pharmaceutical companies abroad, and realize the upgrade of the integrated industrial chain of "pharmaceutical intermediates, raw materials and preparations". In addition, the company will further consolidate and highlight the technological advantages of the company, increase R&D investment and talent introduction, and build a highly educated, high-quality, high-efficiency excellent technical team combining old, middle and young people, and ultimately make the company a stable operation, An industry leader with technological innovation and a long-lasting foundation.

The company will continue to expand the coverage of the sales network, expand the scope and depth of the market, further increase its market share in Europe, and open up other regulated markets such as the United States and Japan. At the same time, the company will actively explore the domestic API and preparation market, use its R&D advantage platform, complete synthetic production equipment and advanced synthesis technology, and combine with the company's existing API production advantages to form an echelon and success with sustainable development capabilities. The series of product portfolios guarantee the company's ability to continue to grow in the future.

In the next three years, the company will focus on imitating the characteristic APIs and downstream preparation products that have been marketed abroad, and gradually start the research and development of biological enzyme technology, using the R&D advantage platform, complete synthetic production equipment and advanced synthesis technology, and the company's existing raw materials Combining the advantages of pharmaceutical production to form a product portfolio with sustainable development capabilities in cascades and series to ensure the company's ability to continue to grow in the future.

The company will vigorously build preparation projects and actively enter the field of preparations; extensively cooperate with domestic and foreign research institutions to further improve the research and development capabilities of new products; strengthen marketing management construction, open up domestic and international high-end markets, and increase the breadth and depth of the company's marketing network; The management level of GMP and EHS, the practice of clean production, ensure the continuous stability of product quality; accelerate the transformation of enterprise information platform, improve the level of enterprise information, and promote the improvement of company operation and management efficiency.

(Source: Securities Daily, original title: Manova was successfully listed as a supplier of specialty APIs and pharmaceutical intermediates)